Yesterday, Jan. 6, 2016, 63 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $29.28 to $2,872,125.00.

Highlighted Stocks Traded by Insiders:

Keryx Biopharmaceuticals (KERX) - FREE Research Report

Madison Greg, who is President and CEO at Keryx Biopharmaceuticals, sold 4,261 shares at $4.83 on Jan. 6, 2016. Following this transaction, the President and CEO owned 110,820 shares meaning that the stake was reduced by 3.7% with the 4,261-share transaction.

Adams Brian, who is VP and General Counsel at Keryx Biopharmaceuticals, sold 3,004 shares at $5.16 on Jan. 6, 2016. Following this transaction, the VP and General Counsel owned 54,454 shares meaning that the stake was reduced by 5.23% with the 3,004-share transaction.

The shares most recently traded at $4.20, down $0.96, or 22.86% since the insider transaction. Historical insider transactions for Keryx Biopharmaceuticals go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 1,638
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 2,649
  • 24-Week # shares bought: 29,984
  • 24-Week # shares sold: 7,090

The average volume for Keryx Biopharmaceuticals has been 2.1 million shares per day over the past 30 days. Keryx Biopharmaceuticals has a market cap of $504.9 million and is part of the health care sector and drugs industry. Shares are down 12.48% year-to-date as of the close of trading on Wednesday.

Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on providing therapies for patients with renal disease in the United States. Currently, there are 6 analysts who rate Keryx Biopharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on KERX - FREE

TheStreet Quant Ratings

rates Keryx Biopharmaceuticals as a

sell

. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, poor profit margins, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full

Keryx Biopharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Q2 Holdings (QTWO) - FREE Research Report

Offerdahl James, who is Director at Q2 Holdings, sold 2,000 shares at $25.38 on Jan. 6, 2016. Following this transaction, the Director owned 15,144 shares meaning that the stake was reduced by 11.67% with the 2,000-share transaction.

The shares most recently traded at $24.31, down $1.07, or 4.4% since the insider transaction. Historical insider transactions for Q2 Holdings go as follows:

  • 4-Week # shares sold: 48,022
  • 12-Week # shares sold: 48,022
  • 24-Week # shares sold: 632,637

The average volume for Q2 Holdings has been 153,000 shares per day over the past 30 days. Q2 Holdings has a market cap of $974.8 million and is part of the technology sector and computer software & services industry. Shares are down 6.07% year-to-date as of the close of trading on Wednesday.

Q2 Holdings, Inc. provides secure cloud-based virtual banking solutions to regional and community financial institutions (RCFIs). Currently, there are 5 analysts who rate Q2 Holdings a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on QTWO - FREE

TheStreet Quant Ratings

rates Q2 Holdings as a

sell

. Among the areas we feel are negative, one of the most important has been generally deteriorating net income. Get the full

Q2 Holdings Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Ensign Group (ENSG) - FREE Research Report

Hubenette Antoinette T., who is Director at Ensign Group, sold 3,333 shares at $22.06 on Jan. 6, 2016. Following this transaction, the Director owned 15,480 shares meaning that the stake was reduced by 17.72% with the 3,333-share transaction.

The shares most recently traded at $21.26, down $0.80, or 3.76% since the insider transaction. Historical insider transactions for Ensign Group go as follows:

  • 4-Week # shares sold: 900
  • 12-Week # shares sold: 2,011
  • 24-Week # shares sold: 3,004

The average volume for Ensign Group has been 310,000 shares per day over the past 30 days. Ensign Group has a market cap of $1.1 billion and is part of the health care sector and health services industry. Shares are down 3.84% year-to-date as of the close of trading on Wednesday.

The Ensign Group, Inc., through its subsidiaries, provides skilled nursing and rehabilitative care services in the United States. It operates through two segments, Transitional, Skilled and Assisted Living Services; and Home Health and Hospice Services. The stock currently has a dividend yield of 0.74%. The company has a P/E ratio of 20.7. Currently, there are 5 analysts who rate Ensign Group a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on ENSG - FREE

TheStreet Quant Ratings

rates Ensign Group as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and solid stock price performance. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Ensign Group Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.